Echo Therapeutics to Present Clinical Study Results of Symphony® tCGM System at the 42nd Critical Care Congress

 Echo Therapeutics to Present Clinical Study Results of Symphony® tCGM System
                      at the 42nd Critical Care Congress

PR Newswire

PHILADELPHIA, Dec. 12, 2012

PHILADELPHIA, Dec. 12, 2012 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system, is
pleased to announce that its clinical study was selected for poster
presentation at the Society of Critical Care Medicine's 42^nd Critical Care
Congress which will be held January 19-23, 2013 in San Juan, Puerto Rico. The
study will be presented by the principal investigator, Stanley A. Nasraway,
M.D., FCCM, during Display and Professor Walk Rounds on Sunday, January 20,
2013 from 12:45-1:45 PM AST.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

The poster, entitled "Accuracy of a Novel Non-Invasive Transdermal Continuous
Glucose Monitor in Critically Ill Patients," will highlight the positive
results from the clinical study of Echo's Symphony tCGM System in critically
ill patients at Tufts Medical Center in Boston, MA.

"We are excited to present these positive clinical study results as we
continue to build awareness of our Symphony tCGM System and the benefits it
can provide to critically ill patients.These clinical results represent the
substantial progress we have made in the Symphony development program," stated
Patrick T. Mooney, M.D., Echo's Chairman and CEO. "We look forward to
beginning our European and U.S. clinical regulatory trials and bringing
Symphony to commercialization to support clinicians in hospital-based glucose
management."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony tCGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure
additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell
diagnostic and transdermal drug delivery products based on its skin permeation
platform technologies, including the Symphony tCGM and Prelude SkinPrep
Systems, the availability of substantial additional equity or debt capital to
support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony tCGM and Prelude SkinPrep Systems. These and other
risks and uncertainties are identified and described in more detail in Echo's
filings with the Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the year ended December 31,
2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Echo undertakes no obligation to publicly update or revise any forward-looking
statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com
 
Press spacebar to pause and continue. Press esc to stop.